ASCO指南更新:癌症患者造血集落刺激因子的使用
该指南更新基于系统评价(33项RCT和16项系统综述),针对成人癌症患者中性粒细胞减少事件的预防或治疗及干细胞动员,给出了集落刺激因子(CSF)的使用推荐。推荐在化疗所致发热性中性粒细胞减少风险约20%或更高时预防性使用CSF,并更新了干细胞动员方案及CSF剂量选择信息。
要点
- 化疗发热性中性粒细胞减少风险≥20%时推荐预防性使用CSF
- 风险<20%但高龄、病史或疾病特征提示高风险者可考虑一级预防
- 干细胞动员可单用CSF、化疗后使用或联合普乐沙福/莫替沙福肽
核心结论
- 化疗所致发热性中性粒细胞减少风险约20%或更高且无同等有效安全替代方案时,推荐预防性使用CSF。
研究设计与样本
- ASCO专家小组基于系统评价制定指南更新,检索PubMed和Cochrane Library(2014年9月1日至2025年8月22日)。
- 系统评价纳入33项随机对照试验和16项系统综述。
主要发现
- 证据体新增内容包括新CSF及生物类似药的批准,以及可用于干细胞动员的额外CXCR4抑制剂。
关键数值与推荐
- 化疗发热性中性粒细胞减少风险约20%或更高时,推荐预防性使用CSF。
- 风险<20%但基于年龄、病史或疾病特征为高风险者,可考虑CSF一级预防。
- 干细胞动员时,CSF可单用、化疗后使用或联合普乐沙福或莫替沙福肽。
临床怎么用
- 根据化疗方案所致发热性中性粒细胞减少风险及患者个体因素决定CSF预防性使用。
- 干细胞动员可根据方案选择CSF单用、化疗后或联合CXCR4抑制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To update the ASCO guideline on use of hematopoietic colony-stimulating factors (CSFs) in patients with cancer. METHODS: A systematic review identified randomized controlled trials (RCTs), meta-analyses, and systematic reviews that addressed use of CSFs for the prevention or treatment of neutropenic events, or for mobilization of stem cells, in adults with cancer. PubMed and the Cochrane Library were searched for articles published from September 1, 2014, to August 22, 2025. ASCO convened an Expert Panel to review the evidence and formulate recommendations. RESULTS: The updated systematic review included 33 RCTs and 16 systematic reviews. Additions to the body of evidence include approval of new CSFs and additional biosimilars, and approval of an additional CXCR4 inhibitor that may be used with CSFs for the mobilization of hematopoietic stem cells. RECOMMENDATIONS: Prophylactic use of CSFs to reduce the risk of febrile neutropenia is warranted when the risk of febrile neutropenia from chemotherapy is approximately 20% or higher and no other equally effective and safe regimen that does not require CSFs is available. For patients receiving chemotherapy with a <20% risk of febrile neutropenia, primary prophylaxis with a CSF may be warranted if patients are at a high risk of febrile neutropenia based on age, medical history, or disease characteristics. For stem-cell mobilization, CSFs may be used either alone, after chemotherapy, or in combination with plerixafor or motixafortide. The guideline also provides information about the dosing and selection of CSFs.Additional information is available at www.asco.org/supportive-care-guidelines.
引用
- Gyawali B, Bohlke K, Dickter JK, et al. WBC Growth Factors: ASCO Guideline Update. J Clin Oncol. 2026. PMID: 41740078. doi:10.1200/JCO-25-02938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。